Pacer Advisors
CYTK icon

Pacer Advisors’s Cytokinetics CYTK Stock Holding History

Pacer Advisors’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.52M Sell
23,057
-4,726
-17% -$300K ﹤0.01% 1049
2025
Q4 		$1.77M Buy
27,783
+12,043
+77% +$749K ﹤0.01% 1170
2025
Q3 		$865K Buy
+15,740
New +$648K ﹤0.01% 1514
2025
Q2 		– Sell
-8,340
Closed -$335K – 3458
2025
Q1 		$335K Sell
8,340
-16,503
-66% -$758K ﹤0.01% 1614
2024
Q4 		$1.17M Buy
24,843
+690
+3% +$35.8K ﹤0.01% 1283
2024
Q3 		$1.28M Buy
24,153
+5,433
+29% +$303K ﹤0.01% 1214
2024
Q2 		$1.01M Buy
18,720
+3,271
+21% +$197K ﹤0.01% 1282
2024
Q1 		$1.08M Buy
+15,449
New +$1.19M ﹤0.01% 1180
2021
Q2 		– Sell
-3,417
Closed -$79K – 1446
2021
Q1 		$79K Sell
3,417
-2,214
-39% -$47.3K ﹤0.01% 1324
2020
Q4 		$117K Buy
5,631
+3,234
+135% +$59.1K ﹤0.01% 1339
2020
Q3 		$52K Buy
+2,397
New +$56.1K ﹤0.01% 1305
2018
Q4 		– Sell
-2,648
Closed -$26K – 668
2018
Q3 		$26K Buy
+2,648
New +$21.2K ﹤0.01% 1171
2018
Q1 		– Sell
-1,250
Closed -$10K – 1059
2017
Q4 		$10K Buy
+1,250
New +$14.2K ﹤0.01% 1143

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Pacer Advisors's CYTK Position: Q1 2026 in Review

Pacer Advisors reduced its Cytokinetics (CYTK) stake by 17% in Q1 2026, selling an estimated $300K and leaving 23,057 shares worth $1.52M. The position accounts for ﹤0.01% of the portfolio, ranked #1049.

Pacer Advisors first reported a position in CYTK in Q4 2017 and has held it in 13 quarters since. The position peaked at $1.77M in Q4 2025. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

  • Pacer Advisors held 23,057 shares of Cytokinetics worth $1.52M as of Q1 2026.
  • Pacer Advisors sold 4,726 Cytokinetics shares in Q1 2026, an estimated $300K.
  • Cytokinetics made up ﹤0.01% of Pacer Advisors's portfolio in Q1 2026, its #1049 holding.
  • Pacer Advisors first reported a position in Cytokinetics in Q4 2017 and has held it in 13 quarters since.
  • Pacer Advisors's Cytokinetics position peaked at $1.77M in Q4 2025.
  • 439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on Pacer Advisors's 13F filing for Q1 2026, filed 6 May 2026.